Template:Ramipril: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
__NOTOC__
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ramipril|{{fontcolor|#6C7B8B|Ramipril}}]]'''''
{{CMG}}; {{AE}} {{AZ}}, {{AM}}
|-
 
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ALTACE<sup>®</sup> FDA Package Insert
'''''For patient information about Ramipril, click [[Ramipril (patient information)|here]].'''''
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril indications and usage|Indications and Usage]]
===Ramipril===
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril dosage and administration|Dosage and Administration]]
* [[Ramipril tablet]]
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril contraindications|Contraindications]]
==Overview==
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril warnings and precautions|Warnings and Precautions]]
'''Ramipril''' tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of [[hypertension]], [[heart failure]], left ventricular dysfunction after [[myocardial infarction]], [[diabetic nephropathy]]. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. [[hypotension]], [[rash]], [[hyperkalemia]], disorder of taste, [[cough]].
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril adverse reactions|Adverse Reactions]]
==Category==
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril drug interactions|Drug Interactions]]
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors.
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril use in specific populations|Use in Specific Populations]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril description|Description]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril clinical studies|Clinical Studies]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril how supplied storage and handling|How Supplied/Storage and Handling]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril patient counseling information|Patient Counseling Information]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril labels and packages|Labels and Packages]]
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Ramipril
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
|-
|}

Latest revision as of 14:29, 25 April 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]

For patient information about Ramipril, click here.

Ramipril

Overview

Ramipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.

Category

Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors.